Table of Contents
Topic Summary
Dubai's Population Growth Fuels PCR Demand
Dubai's population is projected to grow from 3.6 million to 5.8 million by 2040, creating sustained demand for specialist molecular diagnostics services. Mandatory health insurance further strengthens the patient base for licensed molecular biology facilities.
Meydan Free Zone Offers Key Business Advantages
Setting up through Meydan Free Zone gives operators 100% foreign ownership, zero corporate tax on qualifying income, and full profit repatriation. The fully digital licensing process makes market entry fast and cost-effective.
Core Services Covered Under Activity Code 8690.88
This activity code covers PCR testing, gene sequencing, molecular diagnostics, genomic analysis, and related services delivered under DHA licensing standards. It also includes outpatient consultation, preventive screening, and corporate wellness programmes.
Multiple Revenue Streams Available to Operators
Licensed molecular biology facilities can draw income from insurance-funded patients, self-pay clients, and government-referred cases. B2B corporate wellness contracts and group programmes add further diversification.
UAE Healthcare Strategy Backs Sector Expansion
The UAE has made healthcare a strategic priority under We the UAE 2031, with explicit targets for capacity expansion, quality improvement, and medical tourism growth. This policy environment provides regulatory clarity and long-term market confidence for investors.
Know What the Activity Does Not Cover
Hospital inpatient services, general medical practice, and unlicensed wellness services fall outside this activity code and require separate licensing. Operators should ensure their service scope aligns precisely with the molecular biology technologies definition before applying.
No Third-Party Approval or AML Compliance Required
This business activity requires no third-party regulatory approval beyond the standard DHA licensing process. It is also exempt from Anti-Money Laundering compliance requirements, simplifying the administrative setup.
How to Start Molecular Biology Technologies Business in Dubai with Meydan Free Zone
A molecular biology technologies facility, the licensed facility providing specialist PCR testing services, serves a growing patient and consumer base in Dubai.¹
Dubai's population of over 3.6 million, projected to reach 5.8 million by 2040,³ combined with mandatory health insurance and a strong wellness positioning, drives demand for licensed molecular biology technologies facility services.
For operators, a molecular biology technologies facility benefits from specialist positioning, insurance and self-pay revenue streams, and DHA regulatory clarity.²
That sustained demand for quality healthcare, specialist capacity, and population growth is exactly where the opportunity lies.
Sources: Dubai Health Authority. Strategic Plan and Healthcare Statistics, UAE Ministry of Health and Prevention. National Health Strategy, Dubai Media Office, Dubai 2040 Urban Master Plan launch
The UAE has positioned healthcare as a strategic priority under We the UAE 2031, with explicit targets for capacity expansion, quality, Emiratisation, and medical tourism.
Who is this for?
| Audience Segment | Profile |
|---|---|
| Healthcare investors | Groups deploying capital into specialist health services in Dubai, targeting insurance-funded, self-pay, and government-referred patient flows. |
| Clinical founders | Physicians, therapists, and healthcare professionals establishing a licensed specialist practice or centre in Dubai. |
| International health brands | Global healthcare and wellness brands establishing a licensed Dubai operation or franchise. |
Setting up through Meydan Free Zone means 100% foreign ownership, zero corporate tax on qualifying income, full profit repatriation, and a fully digital licensing process, giving you a fast and cost-effective route into the Dubai market.
8690.88 - Molecular Biology Technologies
Under this activity, you are in the business of operating a licensed molecular biology technologies facility providing PCR testing, gene sequencing, molecular diagnostics, genomic analysis, and related molecular biology services.
Services are delivered under DHA licensing and quality standards, with qualified practitioners and appropriate clinical or operational infrastructure.¹
| Category | Scope |
|---|---|
| Specialist Consultation | Assessment. Outpatient consultation, assessment, and treatment planning within molecular biology technologies facility. |
| Core Treatment | Primary services. Pcr testing and related core treatment services. |
| Ongoing Management | Follow-up care. Multi-session treatment plans and chronic or recurring condition management. |
| Preventive Services | Screening and prevention. Preventive screening, early detection, and wellness services within molecular biology technologies facility. |
| Corporate and Group | B2B services. Corporate wellness, group programmes, and institutional service contracts. |
There are some things this activity does not cover. Hospital inpatient services and general medical practice fall under separate codes.
Services outside the defined scope of molecular biology technologies facility are classified under their respective activity codes.
In short: if you are operating a licensed molecular biology technologies facility, you are in. If you are running a hospital, a general practice, or an unlicensed wellness service, you are not.
Third-Party Approval
No third-party approval is required for this business activity.
Anti-Money Laundering Compliance
This business activity is exempt from AML compliance requirements.
